Nutraplus India reports net loss of ₹34.01 lakh in FY26

Nutraplus India Limited reported a net loss of ₹34.01 lakh for the financial year ended March 31, 2026, compared to a net loss of ₹5.01 lakh in the previous year. The company's negative net worth widened to ₹569.02 lakh as of March 31, 2026, from ₹535.01 lakh in the prior year. The Board of Directors approved the audited standalone financial results at a meeting held on May 25, 2026, in Mumbai.

The company recorded total income of ₹15.77 lakh for FY26, entirely derived from other income, as revenue from operations remained nil. Total expenses for the year stood at ₹49.78 lakh. For the quarter ended March 31, 2026, the company reported a net profit of ₹4.46 lakh, compared to a net loss of ₹2.14 lakh in the corresponding period of the previous year.

Financial Performance

Particulars	Year Ended 31.03.2026 (₹ in Lacs)	Year Ended 31.03.2025 (₹ in Lacs)
Total Income	15.77	0.00
Total Expenses	49.78	5.01
Net Profit/(Loss)	(34.01)	(5.01)
Earnings Per Share (Basic)	(0.02)	0.00

Auditor's Observations

Statutory auditors Raman S. Shah & Associates issued a qualified opinion on the standalone financial results. The report highlights material uncertainty regarding the company's ability to continue as a going concern due to the erosion of net worth, loss of assets under SARFAESI proceedings, and discontinuation of business activities. The auditors also noted an inability to comment on the recoverability of trade receivables amounting to ₹33.54 lakh and other current assets of ₹389.42 lakh due to the absence of confirmations and supporting evidence.

Additionally, the auditors stated that the company holds a 33.58% shareholding in Techno Point Mercantile Private Limited but has not prepared consolidated financial statements considering the entity as an associate company. The company has also lost key employees across finance, accounts, legal, production, and marketing functions.

Nutraplus India Limited, a manufacturer of Active Pharmaceutical Ingredients (API) and intermediates, announced its unaudited financial results for the quarter ended June 30, 2020. The Board of Directors approved the quarterly financial results with the Limited Review Report during a meeting held on September 21, 2024. The company reported a net loss of ₹127.90 lakh for the quarter, reflecting significant operational challenges during the pandemic period.

Financial Performance Overview

The company faced severe financial constraints during Q1FY21, with revenue from operations at ₹0.91 lakh and other income contributing ₹2.97 lakh, bringing total income to ₹3.88 lakh. Total expenditures reached ₹131.78 lakh, comprising employee benefit expenses of ₹1.01 lakh, finance cost of ₹6.83 lakh, depreciation and amortisation expenses of ₹119.84 lakh, and other expenditure of ₹6.50 lakh. The company reported a basic and diluted EPS of (₹0.38) for the quarter.

Particulars	Q1FY21 (Jun 2020)	Q4FY20 (Mar 2020)	Q1FY20 (Jun 2019)	FY20 (Mar 2020)
Revenue from Operations	0.91	1,375.98	3,158.56	10,666.81
Other Income	2.97	6.50	3.85	14.35
Total Income	3.88	1,382.48	3,162.40	10,681.16
Employee Benefit Expenses	1.01	215.14	171.50	733.86
Finance Cost	6.83	143.36	159.57	743.16
Depreciation & Amortisation	119.84	120.19	117.97	470.14
Other Expenditure	6.50	953.44	307.02	1,861.47
Total Expenditures	131.78	4,581.77	3,144.78	15,463.78
Net Profit/(Loss)	(127.90)	(3,199.29)	17.62	(4,782.62)
Basic & Diluted EPS (Rs.5/-)	(0.38)	(9.38)	0.05	(14.03)

Operational Challenges and Pandemic Impact

Due to the pandemic situation prevalent in India during 2020 and 2021, the company struggled to carry out its operations on full capacity. However, the company is rendering consultancy services to its clients and is also involved in trading activity in the API industry. The company's operations fall under a single segment, Active Pharmaceutical Ingredient (API).

Auditor's Qualified Review

Raman S. Shah & Associates, Chartered Accountants, issued a qualified limited review report on the unaudited quarterly standalone financial results. The auditors noted non-compliance with listing requirements under the Companies Act, 2013, and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, specifically regarding timely submission of quarterly results. The auditors emphasized that certain financial data and information necessary to perform the limited review were not provided by the company in a timely manner, significantly impairing their ability to perform a comprehensive review.

Corporate Governance and Compliance

The unaudited standalone financial results have been prepared in accordance with Indian Accounting Standard (IND AS) prescribed under section 133 of the Companies Act, 2013. The Board meeting for Q1FY21 results was held on September 21, 2024, with the limited review completed and submitted on the same date. The financial results are available on the company's website www.nutraplusindia.com as well as on the BSE website www.bseindia.com . Mukesh Naik, Managing Director (DIN: 00412896), signed the financial results on behalf of the Board of Directors.